Progenipoietin-1

Increase in plasmacytoid and myeloid dendritic cells by progenipoietin-1, a chimeric Flt-3 and G-CSF receptor agonist, in SIV-Infected rhesus macaques

“…Because the recently developed chimeric receptor agonists were shown to generate higher increases in CD34ϩ cells and CFU than could be obtained by co-injection of native cytokines, we administered the Flt-3/G-SCF receptor agonist, ProGP-1, in the present study [33,34,54]. Here we demonstrated that even in SIVsm-infected macaques, ProGP-1 induced a strong increase of monocytes (12.5ϫ), plasmacytoid DC (6ϫ), and myeloid DC (31-41ϫ) as well as a modest increase in CD4, CD8, and B-cell numbers (3ϫ), whereas plasma virus levels did not increase.…”

“…Recently, progenipoietins (ProGP), a member of a new family of chimeric human Flt-3 and G-CSF receptor agonists, were demonstrated to possess the capacity to mobilize hematopoietic progenitor cells in mice and normal rhesus monkeys and to enhance myeloid and lymphoid recovery from radiation-induced myelosuppression [32][33][34][35][36]. These chimeric molecules were shown to be more effective in mobilizing stem cells than a combined injection of Flt-3 ligand and G-CSF [33][34][35].…”

Neutrophil-derived MMP-9 mediates synergistic mobilization of hematopoietic stem and progenitor cells by the combination of G-CSF and the chemokines GROβ/CXCL2 and GROβT /CXCL2Δ4

“…[1][2][3] A number of agents mobilize PBSCs, including chemotherapy, 4,5 hematopoietic growth factors, particularly granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF), 6 interleukins, 7,8 chemokines, [9][10][11][12] chimeric growth factor fusion proteins, 13,14 sulfated glycans, 15,16 and antibodies against ␤ 1 -integrin (very late activation antigen 4 [VLA-4]) or its receptor (vascular cell adhesion molecule 1 [VCAM-1]). 17,18 Mobilization kinetics are variable, requiring multiday dosing with G-CSF, GM-CSF, interleukin 3 (IL-3), chimeric growth factors, and anti-integrin/receptor antibodies or continuous adenoviral production in the case of IL-17 and stromal cell-derived factor-1␣ (SDF-1␣/CXCL12).…”

Donor pretreatment with progenipoietin-1 is superior to granulocyte colony-stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation

“…16 Progenipoietin-1 (ProGP-1) is a synthetic chimeric molecule that stimulates both G-CSF and Flt-3 receptors and appears to be significantly more potent in the expansion of stem cells and DCs than the combination of both native cytokines due to higher binding affinity. 17,18 We reasoned that ProGP-1 may offer an attractive system to study the effect of DC subsets on GVHD after allogeneic SCT.…”